Neurocrine Biosciences (NBIX: NASDAQ)
Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030, emphasizing substantial market potential. Crinecerfont, an NBIX drug, has shown a positive impact, allowing 63% of adults to lower their glucocorticoid doses.
With a 77% boost in EBIT and a robust free quarterly cash flow of $280.80 million, NBIX demonstrates financial strength. The bullish outlook on NBIX suggests a favorable stance above $99.00-$100.00, with an upside target set at $150.00-$155.00.
With a 77% boost in EBIT and a robust free quarterly cash flow of $280.80 million, NBIX demonstrates financial strength. The bullish outlook on NBIX suggests a favorable stance above $99.00-$100.00, with an upside target set at $150.00-$155.00.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.